IL212175B - Muc1* antibodies - Google Patents
Muc1* antibodiesInfo
- Publication number
- IL212175B IL212175B IL212175A IL21217511A IL212175B IL 212175 B IL212175 B IL 212175B IL 212175 A IL212175 A IL 212175A IL 21217511 A IL21217511 A IL 21217511A IL 212175 B IL212175 B IL 212175B
- Authority
- IL
- Israel
- Prior art keywords
- 1muc
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10320408P | 2008-10-06 | 2008-10-06 | |
| PCT/US2009/059754 WO2010042562A2 (en) | 2008-10-06 | 2009-10-06 | Muc1* antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL212175A0 IL212175A0 (en) | 2011-06-30 |
| IL212175B true IL212175B (en) | 2019-08-29 |
Family
ID=42101177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212175A IL212175B (en) | 2008-10-06 | 2011-04-06 | Muc1* antibodies |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20170204191A1 (https=) |
| EP (3) | EP4083072B1 (https=) |
| JP (3) | JP2012504961A (https=) |
| KR (1) | KR101455447B1 (https=) |
| CN (1) | CN102239182B (https=) |
| CR (1) | CR20110238A (https=) |
| IL (1) | IL212175B (https=) |
| WO (1) | WO2010042562A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170204191A1 (en) | 2008-10-06 | 2017-07-20 | Cynthia C. Bamdad | Muc1* antibodies |
| WO2010042891A2 (en) * | 2008-10-09 | 2010-04-15 | Minerva Biotechnologies Corporation | Method for inducing pluripotency in cells |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP3228629A1 (en) * | 2010-06-16 | 2017-10-11 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| EP2686418A4 (en) | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| CN102716472A (zh) * | 2011-03-31 | 2012-10-10 | 李光辉 | 一种肿瘤疫苗及其合成方法 |
| JP6748430B2 (ja) * | 2012-07-13 | 2020-09-02 | ミネルバ バイオテクノロジーズ コーポレーション | より未分化状態への細胞の誘導方法 |
| CN104717980A (zh) * | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| CA2886161A1 (en) * | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| US9988442B2 (en) | 2013-01-23 | 2018-06-05 | Syddansk Universitet | MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors |
| US10059775B2 (en) | 2014-01-29 | 2018-08-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| CN103880956B (zh) * | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
| CN106414726A (zh) | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US10450376B2 (en) * | 2014-09-16 | 2019-10-22 | Symphogen A/S | Anti-MET antibodies and compositions |
| KR102390359B1 (ko) * | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| CN117442748A (zh) | 2014-10-02 | 2024-01-26 | 希望之城公司 | 多价中间表位、中间表位结合抗体及其用途 |
| US9688750B2 (en) | 2014-10-07 | 2017-06-27 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Anti-nodal antibodies and methods of using same |
| CA2976089C (en) | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| WO2017100670A1 (en) * | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| CN109195992A (zh) * | 2016-04-29 | 2019-01-11 | 本康生物制药（深圳）有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
| CA3050039A1 (en) * | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| CN109971713B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途 |
| JP7779653B2 (ja) * | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| US20200405832A1 (en) * | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| JP2022527144A (ja) * | 2019-01-11 | 2022-05-31 | ミネルヴァ バイオテクノロジーズ コーポレーション | 抗可変ｍｕｃ１＊抗体およびその使用 |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| CN116367857A (zh) | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) * | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| US20230265208A1 (en) * | 2020-07-16 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| BR112023001739A2 (pt) | 2020-07-31 | 2023-02-28 | Scherer Technologies Llc R P | Anticorpo específico para mucina-1 e métodos de uso do mesmo |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
| AU2024206813A1 (en) * | 2023-01-04 | 2025-06-26 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-muc1 antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| WO2025080693A1 (en) | 2023-10-11 | 2025-04-17 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| TWI242563B (en) | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| EP1131106B1 (en) | 1998-11-12 | 2009-06-24 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| WO2001075110A2 (en) * | 2000-03-30 | 2001-10-11 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
| DE60130891T2 (de) | 2000-06-29 | 2008-07-17 | Anthera Pharmaceuticals Inc., San Mateo | Heilmittel für krebs |
| AU9263101A (en) * | 2000-09-11 | 2002-03-26 | Donald W Kufe | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| EP2322929B1 (en) * | 2000-11-27 | 2016-04-06 | Minerva Biotechnologies Corporation | diagnostics, drug screening and treatment for cancer |
| EP1578345A2 (en) | 2001-03-29 | 2005-09-28 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Peptides and antibodies to muc 1 proteins |
| US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| JP2005507876A (ja) | 2001-09-05 | 2005-03-24 | ミナーバ バイオテクノロジーズ コーポレイション | 癌を治療する組成物および方法 |
| US7282567B2 (en) * | 2002-06-14 | 2007-10-16 | Immunomedics, Inc. | Monoclonal antibody hPAM4 |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| WO2003089451A2 (en) | 2002-04-22 | 2003-10-30 | Dyax Corporation | Antibodies specific for mucin polypeptide |
| CA2537263C (en) * | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060173171A1 (en) | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| BRPI0515670A (pt) | 2004-10-04 | 2008-07-29 | Genentech Inc | anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met |
| CA2610292C (en) * | 2005-03-30 | 2015-06-02 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| CN101652469B (zh) | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| US8420591B2 (en) * | 2006-12-08 | 2013-04-16 | Dana-Farber Cancer Institute, Inc. | MUC1 and galectin-3 |
| US20170204191A1 (en) | 2008-10-06 | 2017-07-20 | Cynthia C. Bamdad | Muc1* antibodies |
| CN104717980A (zh) * | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| CA2976089C (en) * | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
-
2009
- 2009-10-06 US US12/574,693 patent/US20170204191A1/en not_active Abandoned
- 2009-10-06 EP EP22161931.5A patent/EP4083072B1/en active Active
- 2009-10-06 CN CN200980148911.6A patent/CN102239182B/zh not_active Expired - Fee Related
- 2009-10-06 EP EP16190400.8A patent/EP3130607B1/en active Active
- 2009-10-06 WO PCT/US2009/059754 patent/WO2010042562A2/en not_active Ceased
- 2009-10-06 EP EP09819788A patent/EP2337801A4/en not_active Withdrawn
- 2009-10-06 KR KR1020117010349A patent/KR101455447B1/ko active Active
- 2009-10-06 US US15/501,768 patent/US10421819B2/en active Active
- 2009-10-06 JP JP2011531128A patent/JP2012504961A/ja active Pending
-
2011
- 2011-04-06 IL IL212175A patent/IL212175B/en active IP Right Grant
- 2011-05-06 CR CR20110238A patent/CR20110238A/es unknown
-
2014
- 2014-11-07 JP JP2014226709A patent/JP6230983B2/ja active Active
-
2017
- 2017-03-23 JP JP2017057024A patent/JP6392923B2/ja active Active
-
2019
- 2019-08-13 US US16/539,247 patent/US11560435B2/en active Active
-
2022
- 2022-12-06 US US18/062,377 patent/US20230295340A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6230983B2 (ja) | 2017-11-15 |
| KR101455447B1 (ko) | 2014-10-27 |
| WO2010042562A3 (en) | 2010-09-30 |
| JP2015071614A (ja) | 2015-04-16 |
| US20230295340A1 (en) | 2023-09-21 |
| US20200239594A1 (en) | 2020-07-30 |
| WO2010042562A2 (en) | 2010-04-15 |
| US10421819B2 (en) | 2019-09-24 |
| JP2012504961A (ja) | 2012-03-01 |
| EP2337801A4 (en) | 2012-07-25 |
| EP4083072A1 (en) | 2022-11-02 |
| EP3130607A2 (en) | 2017-02-15 |
| EP2337801A2 (en) | 2011-06-29 |
| CN102239182A (zh) | 2011-11-09 |
| US20170204191A1 (en) | 2017-07-20 |
| JP2017176174A (ja) | 2017-10-05 |
| IL212175A0 (en) | 2011-06-30 |
| KR20110067153A (ko) | 2011-06-21 |
| JP6392923B2 (ja) | 2018-09-19 |
| CR20110238A (es) | 2012-05-29 |
| EP4083072B1 (en) | 2026-02-18 |
| EP3130607B1 (en) | 2024-04-17 |
| EP3130607A3 (en) | 2017-06-28 |
| CN102239182B (zh) | 2014-07-09 |
| US20180222998A1 (en) | 2018-08-09 |
| US11560435B2 (en) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| IL212175B (en) | Muc1* antibodies | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| EP2337798A4 (en) | SPECIFIC ANTIBODIES OF THE ASB | |
| HUE056626T2 (hu) | Antitestkészítmény | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0917148A2 (pt) | anticorpos anti-cd5 | |
| BRPI0912173A2 (pt) | anticorpos anti-flt3 | |
| BRPI0922800A2 (pt) | anticorpos c-met | |
| DK2342317T3 (da) | Hængende-dråbe-plade | |
| DE602009000234D1 (de) | msignals | |
| BRPI0907376A2 (pt) | Fotobiorretador | |
| BRPI0914649A2 (pt) | Piprazolo-quinazolinas | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| DE602008003972D1 (de) | Sitzrücklehnungsmechanismus | |
| DE602008003521D1 (de) | Sitzrücklehnungsmechanismus | |
| DK2336132T3 (da) | Morpholinpurinderivat | |
| DK2335031T3 (da) | In-line-måler | |
| BRPI0817427A2 (pt) | Anticorpo anti-bst2 | |
| DK2271613T3 (da) | Hydroxymethylcyklohexylaminer | |
| DE602008003970D1 (de) | Strahlstromkalibriersystem | |
| BRPI0907522A2 (pt) | biarlamidas | |
| DE112009000183A5 (de) | Sicherheitsvorreiber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |